Tottori

Researchers are evaluating the effectiveness and safety of two drugs, ozanimod and azathioprine, for treating ulcerative colitis UC in patients who depend on steroids. This observational study focuses on real-world clinical practice in Japan and is sponsored by Bristol-Myers Squibb. The goal is to compare the treatments to better understand their impact on symptom remission and steroid use in UC patients. Participants will be divided into two groups those receiving ozanimod and those receiving azathioprine. Both drugs are given according to their product labels. The study specifically looks at patients who start these medications after beginning oral steroid treatment at doses of 30 mgday or higher, with some differences in symptom requirements for each group. Treatment continuation and steroid use are tracked over a 52-week period. During the study, researchers will monitor participants for steroid-free symptom remission at weeks 12, 24, and 52. They will also measure steroid doses, treatment continuation rates, the duration of steroid-free maintenance, and the time to achieve steroid-free status. Safety will be evaluated by recording adverse events related to the treatments. Participation involves regular observation and data collection over one year.

This research investigates the effects of hypothermia versus normothermia on patients who have undergone extracorporeal cardiopulmonary resuscitation ECPR following out-of-hospital cardiac arrest OHCA. The trial aims to compare mortality risks, neurological outcomes, and adverse events between these two temperature management strategies. The study addresses uncertainties regarding the best temperature control after ECPR, which is a resuscitation method using ECMO to support heart and lung function during cardiac arrest. Participants receive either hypothermia treatment, where their body temperature is cooled to 33-34C using ECMO with a heat exchanger, or normothermia treatment, where the temperature is maintained at 36C. After reaching the target temperature, it is maintained for 24 hours, followed by a 24-hour rewarming period to 36-37.5C, which is then sustained until ECMO ends or for 24 hours post-rewarming. Additional treatments like sedation, muscle relaxants, antipyretics, and circulatory support may be used as needed. During the trial, participants are closely monitored for survival at discharge about 25 days, neurological function using cerebral performance categories, and adverse events during their intensive care stay approximately two weeks. Follow-up assessments occur at 30 days, 90 days, and one year after admission. The study tracks these outcomes to evaluate which temperature management approach might better support recovery after ECPR in OHCA patients.

Researchers are evaluating the overall survival of patients with stage I epithelial ovarian cancer after they have undergone comprehensive staging surgery. This phase III trial compares the outcomes of adjuvant chemotherapy versus observation alone. The study aims to determine whether adding chemotherapy after surgery improves survival in this patient group. Participants will be randomly assigned to one of two groups. One group receives adjuvant chemotherapy, which includes either a combination of paclitaxel and carboplatin or docetaxel and carboplatin, given every three weeks for three to six cycles. Switching between paclitaxel and docetaxel is allowed if adverse events occur. The other group undergoes observation without chemotherapy. During the study, participants will be monitored for overall survival up to 60 months from randomization. Researchers will also assess relapse-free survival within the same timeframe. Evaluations include follow-ups to track disease progression, side effects, and general health. The study ensures participants receive appropriate care and measures outcomes to better understand treatment benefits and risks.